Cheng Zhang1, Yiming Li2, Yang Wang3. 1. Medicine School of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China. 2. Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi, P.R. China. Electronic address: yimli001@163.com. 3. Department of General Surgery, Central Hospital of Xianyang, Xianyang, Shaanxi, P.R. China.
Abstract
BACKGROUND: Previous studies have suggested the abnormal expression of soluble B7-H4 (sB7-H4) in circulation in cancer patients. The aim of present study was to examine the sB7-H4 expression in serum and to investigate the correlations between sB7-H4 levels and clinicopathologic parameters as well as the survival rate of patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Circulating sB7-H4 levels in blood specimens from 93 patients with HCC and 55 healthy volunteers were examined by enzyme-linked immunosorbent assay. The association of sB7-H4 levels with clinicopathologic factors, overall survival (OS), and time to recurrence were statistically analyzed. RESULTS: sB7-H4 levels in HCC patients were significantly higher than that in healthy controls (49.12 ± 3.10 versus 31.66 ± 2.59 ng/mL, P < 0.001). High sB7-H4 levels were correlated with tumor size (P = 0.007), tumor invasion (P = 0.037), tumor differentiation (P = 0.044) and tumor-node metastasis stage (P < 0.001). In addition, high sB7-H4 levels were significantly related to poor OS and higher recurrence probability (P = 0.002, P = 0.014, respectively). High sB7-H4 levels were independent prognostic factors for both OS (hazard ratio = 2.497; 95% confidence interval, 1.133-3.789; P = 0.009) and time to recurrence (hazard ratio = 2.33; 95% confidence interval, 1.247-4.179; P = 0.008). CONCLUSIONS: Detection of sB7-H4 in serum might serve as a clinical predictor in the diagnosis or prediction of clinical outcomes for the patients with HCC.
BACKGROUND: Previous studies have suggested the abnormal expression of soluble B7-H4 (sB7-H4) in circulation in cancerpatients. The aim of present study was to examine the sB7-H4 expression in serum and to investigate the correlations between sB7-H4 levels and clinicopathologic parameters as well as the survival rate of patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Circulating sB7-H4 levels in blood specimens from 93 patients with HCC and 55 healthy volunteers were examined by enzyme-linked immunosorbent assay. The association of sB7-H4 levels with clinicopathologic factors, overall survival (OS), and time to recurrence were statistically analyzed. RESULTS:sB7-H4 levels in HCC patients were significantly higher than that in healthy controls (49.12 ± 3.10 versus 31.66 ± 2.59 ng/mL, P < 0.001). High sB7-H4 levels were correlated with tumor size (P = 0.007), tumor invasion (P = 0.037), tumor differentiation (P = 0.044) and tumor-node metastasis stage (P < 0.001). In addition, high sB7-H4 levels were significantly related to poor OS and higher recurrence probability (P = 0.002, P = 0.014, respectively). High sB7-H4 levels were independent prognostic factors for both OS (hazard ratio = 2.497; 95% confidence interval, 1.133-3.789; P = 0.009) and time to recurrence (hazard ratio = 2.33; 95% confidence interval, 1.247-4.179; P = 0.008). CONCLUSIONS: Detection of sB7-H4 in serum might serve as a clinical predictor in the diagnosis or prediction of clinical outcomes for the patients with HCC.
Authors: Yu Yao; Hongxing Ye; Zengxin Qi; Lianjie Mo; Qi Yue; Aparajita Baral; Dave S B Hoon; Juan Carlos Vera; John D Heiss; Clark C Chen; Jianmin Zhang; Kunlin Jin; Ying Wang; Xingxing Zang; Ying Mao; Liangfu Zhou Journal: Clin Cancer Res Date: 2016-03-21 Impact factor: 12.531
Authors: Ritu Shrestha; Prashanth Prithviraj; Matthew Anaka; Kim R Bridle; Darrell H G Crawford; Bijay Dhungel; Jason C Steel; Aparna Jayachandran Journal: Front Oncol Date: 2018-07-13 Impact factor: 6.244
Authors: Yun Qian; Yiwen Sang; Frederick X C Wang; Bo Hong; Qi Wang; Xinhui Zhou; Tianhao Weng; Zhigang Wu; Min Zheng; Hong Zhang; Hangping Yao Journal: Oncotarget Date: 2016-11-01